SKYE Company Profile and Key Details

SKYE has shown weak momentum, losing -21.3% over the past week and -76.96% over the past quarter, though year-to-date performance is down -69.96%. Short-term trend indicators are bullishly aligned (SMA20 -25.03%, SMA50 -35.44%, SMA200 -65.56%). The stock’s 14-day RSI is 28.5 (weak momentum), while the ATR of 0.12 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -85.22% below its high and over 3.41% above its low. Average 10-day trading volume of 613.03 thousand shares is below the 3-month average of 821.62 thousand, indicating normal recent market interest.

Skye Bioscience, Inc. generated EPS of -$1.29 over the past year. Five-year average earnings growth is 42.99%. Wall Street analysts project EPS growth of -17.03% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 2 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $20.00 to $10.00. The high target offers 2252.94% upside. The low target suggests 1076.47% downside. The mean target is $14.80. This offers 1641.18% upside. Skye Bioscience, Inc. earnings surprise history is a mixed track record. The quarter that ended November 10, 2025, missed forecasts by -3.03%. The prior quarter beat by 29.41%. Over the last six quarters, Apple has recorded several small beats. These include 0.0% in August 09, 2024.

Skye Bioscience, Inc. has 30.99 million shares outstanding. The public float is 18.62 million shares, elevated short interest at 12.94% of float. This equals 2.67 million shares. The short ratio is 7.41 days. Institutional investors hold 67.07% of the float. Insiders own 1.44%. HEPPELL JAMES L holds 500.00 thousand shares, DHILLON PUNIT has 329.82 thousand shares and Grayson Paul A. has 259.70 thousand shares. Over the past six months, insider transactions show net selling. They sold 17.57 thousand shares across 4 transactions.

Skye Bioscience, Inc. (NASDAQ:SKYE) closed at $0.80 USD, losing -$0.05 (-5.89%) from the previous close of $0.85. The stock is currently trading near its 52-week low $0.79 and $5.75. With a market capitalization of about $25.63 million, Skye Bioscience, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~2.68). Key stats such as the average daily volume over the past year has been around 837.45 thousand shares, in line with its 52-week average. Headquartered in San Diego, CA, Skye Bioscience, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Punit S. Dhillon, the company employs approximately 16 people and listed since November 26, 2014. Skye Bioscience, Inc., a biopharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases.

Skye Bioscience, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.86. This means the shares are trading below this model’s fair value.

Skye Bioscience, Inc. trades at a P/E ratio of -0.8, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.77 suggesting the stock is closer to book value. The P/FCF stands at -0.78, also above market averages.

Our AI price prediction model suggests that Skye Bioscience, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -12.94%, with price expected at $0.74 by January 06, 2026, within a range of $0.66 to $0.81 3-Month Outlook: Projected fall of -58.82%, reaching $0.35 by March 20, 2026, with a range of $0.14 to $0.51. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by December 23, 2026, within a range of $0.00 to $0.53.

Skye Bioscience, Inc. (NASDAQ:SKYE) shares are down -69.96% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Skye Bioscience, Inc. trading at a premium to the broader market with a P/E of -0.8. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $15.67, suggesting 1743.53% upside. Our AI forecast model points to short-term weakness (-12.94% over two weeks), a medium-term fall (-58.82% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.